MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer

Yan Lu; Ramaswamy Govindan; Liang Wang; Peng Yuan Liu; Boone Goodgame; Weidong Wen; Ananth Sezhiyan; John Pfeifer; Ya Fei Li; Xing Hua; Yian Wang; Ping Yang; Ming You

doi:10.1093/carcin/bgs100

MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer

Yan Lu, Ramaswamy Govindan, Liang Wang, Peng Yuan Liu, Boone Goodgame, Weidong Wen, Ananth Sezhiyan, John Pfeifer, Ya Fei Li, Xing Hua, Yian Wang, Ping Yang, Ming You

Internal Medicine

Research output: Contribution to journal › Article › peer-review

136 Scopus citations

Abstract

About 30% stage I non-small cell lung cancer (NSCLC) patients undergoing resection will recur. Robust prognostic markers are required to better manage therapy options. MicroRNAs (miRNAs) are a class of small non-coding RNAs of 19-25 nt and play important roles in gene regulation in human cancers. The purpose of this study is to identify miRNA expression profiles that would better predict prognosis of stage I NSCLC. MiRNAs extracted from 527 stage I NSCLC patients were profiled on the human miRNA expression profiling v2 panel (Illumina). The expression profiles were analyzed for their association with cancer subtypes, lung cancer brain metastasis and recurrence/relapse free survival (RFS). MiRNA expression patterns between lung adenocarcinoma and squamous cell carcinoma differed significantly with 171 miRNAs, including Let-7 family members and miR-205. Ten miRNAs associated with brain metastasis were identified including miR-145*, which inhibit cell invasion and metastasis. Two miRNA signatures that are highly predictive of RFS were identified. The first contained 34 miRNAs derived from 357 stage I NSCLC patients independent of cancer subtype, whereas the second containing 27 miRNAs was adenocarcinoma specific. Both signatures were validated using formalin-fixed paraffin embedded and/or fresh frozen tissues in independent data set with 170 stage I patients. Our findings have important prognostic or therapeutic implications for the management of stage I lung cancer patients. The identified miRNAs hold great potential as targets for histology-specific treatment or prevention and treatment of recurrent disease.

Original language	English (US)
Pages (from-to)	1046-1054
Number of pages	9
Journal	Carcinogenesis
Volume	33
Issue number	5
DOIs	https://doi.org/10.1093/carcin/bgs100
State	Published - May 2012

ASJC Scopus subject areas

Cancer Research

Access to Document

10.1093/carcin/bgs100

Cite this

@article{6dba2f96f0d3470aab06ca4b9edcb39b,

title = "MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer",

abstract = "About 30% stage I non-small cell lung cancer (NSCLC) patients undergoing resection will recur. Robust prognostic markers are required to better manage therapy options. MicroRNAs (miRNAs) are a class of small non-coding RNAs of 19-25 nt and play important roles in gene regulation in human cancers. The purpose of this study is to identify miRNA expression profiles that would better predict prognosis of stage I NSCLC. MiRNAs extracted from 527 stage I NSCLC patients were profiled on the human miRNA expression profiling v2 panel (Illumina). The expression profiles were analyzed for their association with cancer subtypes, lung cancer brain metastasis and recurrence/relapse free survival (RFS). MiRNA expression patterns between lung adenocarcinoma and squamous cell carcinoma differed significantly with 171 miRNAs, including Let-7 family members and miR-205. Ten miRNAs associated with brain metastasis were identified including miR-145*, which inhibit cell invasion and metastasis. Two miRNA signatures that are highly predictive of RFS were identified. The first contained 34 miRNAs derived from 357 stage I NSCLC patients independent of cancer subtype, whereas the second containing 27 miRNAs was adenocarcinoma specific. Both signatures were validated using formalin-fixed paraffin embedded and/or fresh frozen tissues in independent data set with 170 stage I patients. Our findings have important prognostic or therapeutic implications for the management of stage I lung cancer patients. The identified miRNAs hold great potential as targets for histology-specific treatment or prevention and treatment of recurrent disease.",

author = "Yan Lu and Ramaswamy Govindan and Liang Wang and Liu, {Peng Yuan} and Boone Goodgame and Weidong Wen and Ananth Sezhiyan and John Pfeifer and Li, {Ya Fei} and Xing Hua and Yian Wang and Ping Yang and Ming You",

note = "Funding Information: This work was supported by National Institutes of Health grant 1R01CA129533-01A1 (to M.Y.), fund from A Healthier Wisconsin (to Y.L. and P.-Y.L.) and a fund from Department of Laboratory Medicine and Pathology, Mayo Clinic (to L.W.).",

year = "2012",

month = may,

doi = "10.1093/carcin/bgs100",

language = "English (US)",

volume = "33",

pages = "1046--1054",

journal = "Carcinogenesis",

issn = "0143-3334",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer

AU - Lu, Yan

AU - Govindan, Ramaswamy

AU - Wang, Liang

AU - Liu, Peng Yuan

AU - Goodgame, Boone

AU - Wen, Weidong

AU - Sezhiyan, Ananth

AU - Pfeifer, John

AU - Li, Ya Fei

AU - Hua, Xing

AU - Wang, Yian

AU - Yang, Ping

AU - You, Ming

N1 - Funding Information: This work was supported by National Institutes of Health grant 1R01CA129533-01A1 (to M.Y.), fund from A Healthier Wisconsin (to Y.L. and P.-Y.L.) and a fund from Department of Laboratory Medicine and Pathology, Mayo Clinic (to L.W.).

PY - 2012/5

Y1 - 2012/5

N2 - About 30% stage I non-small cell lung cancer (NSCLC) patients undergoing resection will recur. Robust prognostic markers are required to better manage therapy options. MicroRNAs (miRNAs) are a class of small non-coding RNAs of 19-25 nt and play important roles in gene regulation in human cancers. The purpose of this study is to identify miRNA expression profiles that would better predict prognosis of stage I NSCLC. MiRNAs extracted from 527 stage I NSCLC patients were profiled on the human miRNA expression profiling v2 panel (Illumina). The expression profiles were analyzed for their association with cancer subtypes, lung cancer brain metastasis and recurrence/relapse free survival (RFS). MiRNA expression patterns between lung adenocarcinoma and squamous cell carcinoma differed significantly with 171 miRNAs, including Let-7 family members and miR-205. Ten miRNAs associated with brain metastasis were identified including miR-145*, which inhibit cell invasion and metastasis. Two miRNA signatures that are highly predictive of RFS were identified. The first contained 34 miRNAs derived from 357 stage I NSCLC patients independent of cancer subtype, whereas the second containing 27 miRNAs was adenocarcinoma specific. Both signatures were validated using formalin-fixed paraffin embedded and/or fresh frozen tissues in independent data set with 170 stage I patients. Our findings have important prognostic or therapeutic implications for the management of stage I lung cancer patients. The identified miRNAs hold great potential as targets for histology-specific treatment or prevention and treatment of recurrent disease.

AB - About 30% stage I non-small cell lung cancer (NSCLC) patients undergoing resection will recur. Robust prognostic markers are required to better manage therapy options. MicroRNAs (miRNAs) are a class of small non-coding RNAs of 19-25 nt and play important roles in gene regulation in human cancers. The purpose of this study is to identify miRNA expression profiles that would better predict prognosis of stage I NSCLC. MiRNAs extracted from 527 stage I NSCLC patients were profiled on the human miRNA expression profiling v2 panel (Illumina). The expression profiles were analyzed for their association with cancer subtypes, lung cancer brain metastasis and recurrence/relapse free survival (RFS). MiRNA expression patterns between lung adenocarcinoma and squamous cell carcinoma differed significantly with 171 miRNAs, including Let-7 family members and miR-205. Ten miRNAs associated with brain metastasis were identified including miR-145*, which inhibit cell invasion and metastasis. Two miRNA signatures that are highly predictive of RFS were identified. The first contained 34 miRNAs derived from 357 stage I NSCLC patients independent of cancer subtype, whereas the second containing 27 miRNAs was adenocarcinoma specific. Both signatures were validated using formalin-fixed paraffin embedded and/or fresh frozen tissues in independent data set with 170 stage I patients. Our findings have important prognostic or therapeutic implications for the management of stage I lung cancer patients. The identified miRNAs hold great potential as targets for histology-specific treatment or prevention and treatment of recurrent disease.

UR - http://www.scopus.com/inward/record.url?scp=84860466755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860466755&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgs100

DO - 10.1093/carcin/bgs100

M3 - Article

C2 - 22331473

AN - SCOPUS:84860466755

SN - 0143-3334

VL - 33

SP - 1046

EP - 1054

JO - Carcinogenesis

JF - Carcinogenesis

IS - 5

ER -

MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this